Engineered immune cells show promise against tough childhood cancers
NCT ID NCT02315612
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This phase 1 trial tested a new therapy called CD22-CAR T cells in 134 children and young adults (ages 1-39) with B-cell leukemia or lymphoma that had not been cured by standard treatments. The therapy involves taking a patient's own white blood cells, modifying them in a lab to target the CD22 protein on cancer cells, and infusing them back. The study found that the treatment was safe enough to continue testing and led to complete or partial remission in some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD22-CAR T cells (a type of immune cell therapy)
What this could lead to
If successful, this could lead to a new treatment option for young people with hard-to-treat B-cell cancers that have not responded to standard therapy.
What could go wrong
This is an early-phase trial, so the treatment may not work for everyone and can cause serious side effects like severe immune reactions. Long-term benefits are not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.